Diabetes Day for Primary Care Providers

Albany, NY

Vertical Tabs


With an aging population and longer life expectancy come an increased prevalence of chronic diseases and conditions, including diabetes. The percentage of United States adults with diabetes (including both diagnosed and undiagnosed) is at least 8.3% (based on 2010 numbers), far exceeding the capacity of the specialists, the endocrinologists, to manage these patients. For example, each year there are more than 28 million ambulatory care visits with diabetes as primary diagnosis.

The vast majority of patients with type 2 diabetes are managed in the primary care setting. Primary care clinicians need to accept the challenge to more aggressively treat their patients with diabetes.  This can help patients reach optimal glycemic goals, reduce the burden of the disease, and improve the patient’s health outcomes and quality of life. As the recognized experts on this metabolic condition, endocrinologists are the content experts and lead authorities in diabetes clinical research and its application to clinical practice. Therefore, they are uniquely qualified to provide continuing education regarding diabetes and its care to primary care physicians.

More effective education for primary care physicians and clinicians can help improve cardiometabolic control in patients with diabetes. With more knowledge, primary care physicians can more effectively educate their patients about the disease and the value of preventive therapy. Awareness of barriers, identification of strategies to overcome obstacles, and further opportunities for practitioners to problem-solve strategies to assist patients in managing a chronic illness that requires numerous daily decisions are all needed.

The program will comprehensively address the complex challenges faced by primary care providers in the areas of diabetes prevention, diagnosis, and treatment, as well as co-morbid conditions that make diabetes such a complex disease. The education will provide an in-depth look at current guidelines, clinical thinking, and management practices to successfully treat diabetes and modifiable cardiometabolic issues. An ethnically and clinically-diverse patient population will also be used to develop interactive “real patient-case” vignettes to help learners better understand the real-world challenges and cultural health disparities of patients with diabetes, as well as how to best address their care.

Target Audience

Primary care providers including MDs, DOs, NPs, PAs, RNs, CDEs, Pharmacists and other interested health care providers.

7:00 - 8:00 am       Registration - Exhibit Hall Open
8:00 - 8:10 am   Welcome Remarks & Objectives Review
    Robert Busch, MD, FACE – Local Program Chair
8:10 - 8:35 am   Type 2 Diabetes and Obesity Epidemic: Pathophysiology, Diagnosis and
    Treatment Goals
    Matthew Leinung, MD, FACE
8:35 - 8:45 am   Q&A
8:45 - 9:15 am   Treatment of Type 2 Diabetes: What Have We Learned?
    Michael Walker, MD, FACE
9:15 - 9:25 am   Q&A
9:25 - 9:50 am   Addressing the Incretin Defect in Treatment of Type 2 Diabetes
    Robert Busch, MD, FACE
9:50 - 10:00 am   Q&A
10:00 - 10:30 am   Break – Exhibit Hall Open
10:30 - 11:00 am   Cardiovascular Risk Reduction and Other Co-Morbidities in Type 2 Diabetes
    Jay Watsky, MD, FACE
11:00 - 11:10 am   Q&A
11:10 - 11:45 am   Insulin Initiation and Intensification
    Matthew Leinung, MD, FACE
11:45 - 11:55 am   Q&A
11:55 - 12:20 pm   Education & Lifestyle
    Eileen Hogan, NP, CDE
12:20 - 12:30 pm   Q&A
12:30  -  1:00 pm   Case Presentation: Management of Diabetes, Applying Science to Practice
    Robert Busch, MD, FACE
1:00 pm   Adjourn
Educational Objectives
After participating in the continuing education program, participants will have an improved ability to:
  • Describe the different methods available to diagnose type 2 diabetes.
  • Select appropriate classes of therapeutic agents designed to treat specific diabetic pathophysiologic defects.
  • Identify patients at risk for prediabetes and diabetes.
  • Implement strategies to reduce the risk of adverse outcomes for prediabetes and diabetes patients by meeting treatment goals for glucose, lipids, and blood pressure.
  • Outline the clinical considerations in the selection of pharmacotherapy for type 2 diabetes, including degree of A1c lowering needed, patient specific concerns, adverse effects, comorbidities, and contraindications.
  • Discuss the role of combination therapy and when it should be initiated based on A1c goals.
  • Explain the implications of recent clinical trials and meta-analyses on clinical practice decisions.
  • State the modes of action and clinical potential of therapeutic agents, including amylin agonists, incretin-based therapies, and other more recently introduced agents in the management of patients with type 2 diabetes.
  • Differentiate new and traditional treatment strategies with respect to factors, such as A1c lowering potential, route of administration, effects on weight and/or CV risk, including whether or not they can be used as part of mono- or combination-therapy strategies.
  • Describe the relationship between major CV risk factors and CVD outcomes.
  • Select therapeutic modalities available to practitioners to improve the CV risk factors.
  • Recognize the implications of recent large trials on clinical decisions guiding choice and targets for blood pressure and lipid abnormalities.
  • Discuss other co-morbid/microvascular conditions associated with type 2 diabetes patients.
  • Select strategies how to introduce insulin to patients who are candidates for this therapy.
  • Differentiate human insulin and insulin analogs from each other, including pharmacokinetics, predictability, incidence of hypoglycemia, weight gain, and patient administration.
  • Describe how to intensify an insulin regimen as needed to achieve glycemic targets.
  • Examine available insulin modalities (vials, devices) for delivery and their use in the outpatient setting.
  • List approaches to incorporate patient education in self-management treatment methods.
  • Develop strategies to involve other healthcare professionals to support the care of patients with type 2 diabetes.
  • State the activity and nutritional recommendations for patients with type 2 diabetes.
  • Summarize steps on how to apply the knowledge gained from this activity to the learners practice to improve and document the disease management outcomes for patients with type 2 diabetes.

Robert Busch, MD, FACE

Local Program Chair

 Managing Partner, Physician

 The Endocrine Group, LLP

 Albany, NY


Eileen Hogan, NP, CDE

 Certified Diabetes Educator

 The Endocrine Group, LLP

Albany, NY


Matthew Leinung, MD, FACE

 Chief, Division of Endocrinology

 AMC Endocrinology Group

 Albany, NY


Michael Walker, MD, FACE

Board Certified in Endocrinology, Diabetes and Metabolism, Internal Medicine 

The Endocrine Group, LLP

 Albany, NY


Jay Watsky, MD, FACE

 Board Certified in Endocrinology, Diabetes and Metabolism, Internal Medicine

 The Endocrine Group, LLP

 Albany, NY



Steering/Program Committee

George Grunberger, MD, FACP, FACE

Chairman, Grunberger Diabetes Institute Clinical Professor, Internal Medicine and Molecular Medicine & Genetics

Wayne State University School of Medicine


Alan J. Garber, MD, PhD, FACE

Professor Departments of Medicine,

Biochemistry and Molecular Biology and Molecular and Cellular Biology

Baylor College of Medicine

Houston, TX

President, American Association of Clinical Endocrinologists


Etie S. Moghissi, MD, FACP, FACE

Private Practice, Endocrinology and Diabetes, Marina del Rey, California

Associate Clinical Professor of Medicine, UCLA


Fatma AlMarashi, MD, FACE

Medical Director at University Hospital,

Part of the Mohammed Bin Rashid Academic Medical Center

Dubai Healthcare City


David S. H. Bell, MD, MB, FACE, FACP

Adjunct Clinical Professor of Medicine University of Alabama Medical School Birmingham, AL


Felice A. Caldarella, MD, FACP, CDE, FACE

Research Director, Diabetes and Endocrine Associates of Hunterdon

Hunterdon Medical Center


Jeffrey R. Garber, MD, FACP, FACE

President, American College of Endocrinology

Chief, Endocrinology Harvard Vanguard Medical Associates

Associate Professor of Medicine Harvard Medical School


Chris K. Guerin, MD, FNLA, FACE

Assistant Clinical Professor of Medicine University of California, San Diego


Yehuda Handelsman, MD, FACP, FACE, FNLA

Medical Director & Principal Investigator, Metabolic Institute of America

Immediate Past President, American Association of Clinical Endocrinologists Chair & Program Director,

World Congress on Insulin Resistance, Diabetes & CVD


Daniel L. Hurley, MD, FACE

Consultant, Division of Endocrinology, Diabetes, Metabolism,

Nutrition, Department of Internal Medicine, Mayo Clinic,

Rochester, MN

Assistant Professor of Medicine, College of Medicine, Mayo Clinic


W. Reid Litchfield, MD, FACE, ECNU, FRCP(C)

Adjunct Associate Professor Touro University

Henderson, NV


Paul David Rosenblit, MD, FACE

Clinical Professor, Medicine (Div. Endocrinology, Diabetes, Metabolism)

University California, Irvine (UCI), School of Medicine,

Irvine, CA

Co-Director Diabetes Out-Patient Clinic UCI Medical Center,

 Orange, CA

Director, Diabetes/Lipid Management & Research Center,

Huntington Beach, CA


Stanley Steven Schwartz, MD, FACE

Associate Professor of Medicine - Emiritus,

University of Pennsylvania Philadelphia, PA


Jerome E. Thurman, MD, FACE

Assistant Professor of Clinical Medicine

 Saint Louis University School of Medicine

Saint Louis, MO


Joseph Michael Tibaldi, MD

Assistant Clinical Professor of Medicine Weill Cornell Medical College

Queens, NY

Diabetes and Endocrine Associates

Fresh Meadows, NY


Jeff Unger, MD

Director, Metabolic Studies,

Catalina Research Institute and Unger Primary Care Center

Chino, CA


PIM Disclosure Summary:

The following PIM planners and managers, Laura Excell, ND, NP, MS, MA, LPC, NCC; Trace Hutchison, PharmD; Samantha Mattiucci, PharmD; Jan Schultz, RN, MSN, CCMEP; and Patricia Staples, MSN, NP-C, CCRN hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.


Additional Disclosure Information to be provided as soon as it is available

Corporate Support

AACE would like to acknowledge the following companies that have provided support for this educational activity.

Boehringer Ingelheim Pharmaceuticals, Inc.,

which was made possible, in part, through collaboration with Eli Lilly and Company

Novo Nordisk Inc.

sanofi-aventis U.S.

*Accurate at time of posting

Physician Credit

The American Association of Clinical Endocrinologists (AACE) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The American Association of Clinical Endocrinologists (AACE) designates this live activity for a maximum of 4.5 AMA PRA Category 1 Credit(s)™.

Physicians should only claim credit commensurate with the extent of their participation in the activity.

Nursing Credit

Credit Designation

This educational activity for 4.5 contact hours is provided by Postgraduate Institute for Medicine.

Accreditation Statement

Postgraduate Institute for Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

Postgraduate Institute for Medicine is approved by the California Board of Registered Nursing, Provider Number 13485 for 4.5 contact hours.

There is no fee for this educational activity. A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be mailed to you within three weeks.

For information about ACPE and ANCC accreditation, please contact Postgraduate Institute for Medicine at (303) 799-1930 or information@pimed.com.

Pharmacist Credit

Postgraduate Institute for Medicine is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Postgraduate Institute for Medicine designates this continuing education activity for 4.5 contact hour(s) (0.45 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number - 0809-9999-12-356-L01-P)

Type of Activity: Knowledge-Based

For information about ACPE and ANCC accreditation, please contact Postgraduate Institute for Medicine at (303) 799-1930 or information@pimed.com.


The Desmond

660 Albany Shaker Road

Albany, NY 12211

(518) 869-8100


Registration Fees

There is no registration fee to attend this meeting. However, we do request that you pre-register by completing this form. AACE Membership is NOT required to attend this program.

Program Fee
There is no registration fee to attend this meeting. We do request that you pre-register by completing this form. AACE Membership is NOT required to attend this program.
Registration Type
Contact Information
Cancellation Policy
AACE reserves the right to cancel this course based on enrollment or conditions beyond our control. In the case of program cancellation, each pre-registrant will be notified by phone and/or email. AACE is not responsible for any costs incurred due to program cancellation, such as airline or hotel penalties.
E-mail Disclaimer
By entering your email address, you agree that your email address can be used for future correspondence from the American Association of Clinical Endocrinologists. This information would include, but is not limited to certifications, program information and future advertisements.
Finish Registration
A Printed Syllabus will NOT be distributed for this activity.
This question is for testing whether you are a human visitor and to prevent automated spam submissions.